Skip to main content
SpringerLink
Log in

Biocapital and Innovation Paths: The Exploitation of Regenerative Medicine

  • Chapter
The Global Dynamics of Regenerative Medicine

Part of the book series: Health, Technology and Society ((HTE))

Abstract

This chapter examines the dynamics of innovation in regenerative medicine (RM), focusing specifically on the contemporary activities of European-based RM firms. For the purposes of this chapter the term ‘innovation’ is taken to refer to the development and deployment of novel technologies. As Chapters 1 and 2 have shown, ‘regenerative medicine’ is a heterogeneous domain incorporating a range of technologies. Different technological options within RM can be complementary or in competition with one another depending on how their deployment is envisaged. The heterogeneity of RM is not limited to specific material technologies, but also encompasses different models of how its products might be delivered in the clinic, how they might be reimbursed under different financial health care regimes, and different aims in terms of the diseases and patient populations particular RM technologies are best suited to address. There are thus different pathways which innovation in RM can potentially follow.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  • Adams, S. (2012) Girl, 10, receives major vein grown from own stem cells, The Telegraph, 14 June 2012. Available at http://www.telegraph.co.uk/health/healthnews/9329455/Girl-10-receives-major-vein-grown-from-own-stem-cells.html, accessed 18 June 2012.

  • Atala, A. (2007) Engineering tissues, organs and cells, Journal of Tissue Engineering and Regenerative Medicine, 1: 83–96.

    Article  Google Scholar 

  • Bahadur, G., M. Morrison and L. Machin (2010) Beyond the ‘embryo question’: human embryonic stem cell ethics in the context of biomaterial donation in the UK, Reproductive Biomedicine Online, 21: 868–874.

    Article  Google Scholar 

  • Bajada, S., I. Mazakova, J. B. Richardson and N. Ashammakhi (2008) Updates on stem cells and their applications in regenerative medicine, Journal of Tissue Engineering and Regenerative Medicine, 2(4): 169–183.

    Article  Google Scholar 

  • Barber, B. and T. Odean (2001) Boys will be boys: gender, overconfidence and common stock investment, Quarterly Journal of Economics, 116(1): 261–292.

    Article  Google Scholar 

  • Belmonte, J. C. I., J. Ellis, K. Hochedlinger and S. Yamanaka (2009) Induced pluripotent stem cells and reprogramming: seeing the science through the hype, Nature Reviews: Genetics, 10(December): 878–883.

    Article  Google Scholar 

  • Birch, K. (2006) The neoliberal underpinnings of the bioeconomy: the ideological discourses and practices of economic competitiveness, Genomics, Society and Policy, 2: 1–15.

    Article  Google Scholar 

  • Borup, M., N. Brown, K. Konrad and H. Van Lente (2006) The sociology of expectations in science and technology, Technology Analysis and Strategic Management, 18: 285–298.

    Article  Google Scholar 

  • Bottazzi, L. and M. Da Rin (2002) European venture capital, Economic Policy, April: 230–269.

    Google Scholar 

  • Brown, N., A. Kraft and P. Martin (2006) The promissory pasts of blood stem cells, BioSocieties, 1(3): 329–348.

    Article  Google Scholar 

  • Brown, N., L. Machin and C. McLeod (2011) Immunitary bioeconomy: the economization of life in the international cord blood market, Social Science and Medicine, 72(7): 1115–1122.

    Article  Google Scholar 

  • Brown, N., B. Rappert and A. Webster (eds) (2000) Contested Futures: A Sociology of Prospective Techno-Science. Aldershot: Ashgate.

    Google Scholar 

  • Coenen, L., J. Moodysson and B. Asheim (2004) Nodes, networks and proximities: on the knowledge dynamics of the Medicon Valley Biotech Cluster, European Planning Studies, 12(7): 1003–1018.

    Google Scholar 

  • Cooke, P. (2001) New economy innovation systems: biotechnology in Europe and the USA, Industry and Innovation, 8: 267–289.

    Article  Google Scholar 

  • Cooke, P. (2004) Life science clusters and regional science policy, Urban Studies, 41(5/6): 1113–1131.

    Article  Google Scholar 

  • Cooper, M. (2008) Life as Surplus: Biotechnology & Capitalism in the Neoliberal Era. Seattle: University of Washington Press.

    Google Scholar 

  • Daar, A. S. and H. L. Greenwood (2007) A proposed definition of regenerative medicine, Tissue Engineering, 1(3): 179–184.

    Google Scholar 

  • Daley, G. Q. and D. T. Scadden (2008) Prospects for stem cell-based therapy, Cell, 132(4): 544–548.

    Article  Google Scholar 

  • Dumit, J. (2003) A pharmaceutical grammar: Drugs for life and direct-to-consumer advertising in an era of surplus health. Unpublished paper, Department of Anthropology, University of California, Davis.

    Google Scholar 

  • Ernst and Young (2009) Beyond borders: the global biotechnology report 2009, Biotechnology Journal, 4: 1108–1110.

    Article  Google Scholar 

  • Fairchild, P. J., S. Cartland, K. F. Nolan and H. Waldmann (2004) Embryonic stem cells and the challenge of transplantation tolerance, Trends in Immunology, 25(9): 465–470.

    Article  Google Scholar 

  • Fairchild, P. J., N. J. Robertson, S. L. Minger and H. Waldmann (2007) Embryonic stem cells: protecting pluripotency from alloreactivity, Current Opinion in Immunology, 19: 596–602.

    Article  Google Scholar 

  • Faulkner, A. (2009) Device or drug? Governation of tissue engineering, in A. Faulkner (ed.) Medical Technology into Healthcare and Society: A Sociology of Devices, Innovation and Governance. Basingstoke: Palgrave Macmillan, pp. 159–187.

    Google Scholar 

  • Faulkner, A., I. Geesink, J. Kent and D. Fitzpatrick (2003) Human tissue engineered products — drugs or devices? Tackling the regulatory vacuum, British Medical Journal, 326: 1159–1160.

    Article  Google Scholar 

  • Gardner, R. L. (2007) Stem cells and regenerative medicine: principles, prospects and problems, Comptes Rendus Biologies, 330(6–7): 465–473.

    Article  Google Scholar 

  • Geels, F. W. (2002) Technological transitions as evolutionary reconfiguration processes: a multi-level perspective and a case-study, Research Policy, 31(8/9): 1257–1274.

    Article  Google Scholar 

  • Gruber, A. (2009) Biotech funding trends: insights from entrepreneurs and investors, Biotechnology Journal, 4: 1102–1105.

    Article  Google Scholar 

  • Guertin, P. (2009) The biotechnology industry: what’s next? Biotechnology Journal, 4: 1124–1131.

    Article  Google Scholar 

  • Hicks, D. and J. Katz (1996) Hospitals: the hidden research system, Science and Public Policy, 23(5): 297–304.

    Google Scholar 

  • Hirshleifer, D. (2001) Investor psychology and asset pricing, Journal of Finance, 56(4): 1533–1597.

    Article  Google Scholar 

  • Hope, W. (2009) Conflicting temporalities: state, nation, economy and democracy under global capitalism, Time and Society, 18: 62–85.

    Article  Google Scholar 

  • Hopkins, M. M. (2006) The hidden research system: the evolution of cytogenetic testing in the national health service, Science as Culture, 15(3): 253–276.

    Article  Google Scholar 

  • Hu, B-Y., J. P. Weick, J. Yu, L. -X. Ma, X.-Q. Zhang, J. A. Thomson and S. -C. Zhanga (2010) Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency, PNAS, 107(9): 4335–4340.

    Article  Google Scholar 

  • ISSCR (2008) ISSCR guidelines for the clinical translation of stem cells. International Society for Stem Cell Research. Available at http://www.isscr.org//clinical_trans/pdfs/ISSCRGLCIinicalTrans.pdf, accessed 19 June 2012.

    Google Scholar 

  • Kemp, P. (2006) History of regenerative medicine: looking backwards to move forwards, Regenerative Medicine, 1(5): 653–669.

    Article  Google Scholar 

  • Kent, J., A. Faulkner, I. Geesink and D. Fitzpatrick (2006) Culturing cells, reproducing and regulating the self, Body and Society, 12(2): 1–23.

    Article  Google Scholar 

  • Kewell, B. and A. Webster (2009) A tale of ‘cautious pessimism’: biotechnology, recession and the ‘new economy’, Biotechnology Journal, 4: 1106–1110.

    Article  Google Scholar 

  • Leydesdorff, L. and H. Etzkowitz (1996) Emergence of a triplehelix of university-industry-government relations, Science and Public Policy, 23: 279–286.

    Google Scholar 

  • Linsley, P. and A. Linsley (2009) Cultural theory of risk and the credit crisis, Journal of Risk and Governance, 1: 3.

    Google Scholar 

  • Lysaght, M., A. Jaklenec and E. Deweerd (2008) Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics, Tissue Engineering: Part A, 14(2): 305–319.

    Article  Google Scholar 

  • Machin, L., N. Brown and D. McLeod (2012) ‘Two’s company — Three’s a crowd’: the collection of umbilical cord blood for commercial stem cell banks in England and the midwifery profession, Midwifery, 28(3): 358–365.

    Article  Google Scholar 

  • Marks and Clerk UK (2009) News item: funding gap will lead to further consolidation of biotech industry, finds new Marks and Clerk Research, May. Available at http://www.marks-clerk.com/uk/attorneys/news/mewsitem.aspx?item=270, accessed 26 May 2009.

    Google Scholar 

  • Marrus, S. (2009) How to save biotech. The Scientist.com. Available at http://www.thescientist.com/news/print/55425/, accessed 15 January 2010.

    Google Scholar 

  • Martin, P., N. Brown and A. Kraft (2008) From Bedside to Bench? Communities of Promise, Translational Research and the Making of Blood Stem Cells. Science as Culture, 17(1): 29–41

    Article  Google Scholar 

  • Martin, P., R. Hawksley and A. Turner (2009) The Commercial Development of Cell Therapy-Lessons for the Future? Survey of the Cell Therapy Industry and the Main Products in Use and Development. Part 1: Summary of Findings. EPSRC Remedi Report, Institute for Science and Society, The University of Nottingham.

    Google Scholar 

  • Martin, P. A., C. Coveny, A. Kraft, N. Brown and P. Bath (2006) The commercial development of stem cell technology: lessons from the past, strategies for the future, Regenerative Medicine, 1(6): 801–807.

    Article  Google Scholar 

  • Mason, C. (2007) Regenerative medicine 2.0, Regenerative Medicine, 2(1): 11–18.

    Article  Google Scholar 

  • McAllister, T. N., N. Dussere, M. Maruszewski and N. L’Heureux (2008) Cell-based therapeutics from an economic perspective: primed for a commercial success or a research sinkhole?, Regenerative Medicine 3(6): 925–937.

    Article  Google Scholar 

  • Medical Research Council (2012) A Strategy for UK Regenerative Medicine. Available at http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d=MRC008534, accessed 16 May 2012.

    Google Scholar 

  • Mirowski, P. (2011) Science Mart: Privatizing American Science. Cambridge: Harvard University Press.

    Book  Google Scholar 

  • Morrison, M. and L. Cornips (2012) Exploring the role of dedicated online biotechnology news providers in the innovation economy, Science Technology and Human Values, 37(May 2012): 262–285.

    Article  Google Scholar 

  • Nature Biotechnology (2011) Profile: Irv Weismann, Nature Biotechnology, 29(3): 194.

    Article  Google Scholar 

  • Nerem, R. M. (2010) Regenerative medicine: the emergence of an industry, Journal of the Royal Society Interface, 7(53): S771–S775.

    Article  Google Scholar 

  • OECD (2009) The bioeconomy to 2030 designing a policy agenda: main findings and policy conclusions, OECD International Futures Project. Available at www.oecd.org/futures/bioeconomy/2030, accessed 10 October 2009.

  • Owen-Smith, J., M. Riccaboni, F. Pammolli and W. Powell (2002) A comparison of U.S. and European university-industry relations in the life sciences, Management Science, 48(1): 24–43.

    Article  Google Scholar 

  • Park, M. (2012) Texas board approves rules on use of stem cells, New York Times, 13 April 2012. Available at http://www.nytimes.com/2012/04/14/us/new-rules-on-adult-stem-cells-approved-in-texas.html, accessed 23 June 2012.

  • Pickering, A. (1995) The Mangle of Practice: Time, Agency and Science. Chicago: University of Chicago Press.

    Book  Google Scholar 

  • Plagnol, A. C., E. Rowley, P. Martin and F. Livesey (2009) Industry perceptions of barriers to commercialisation of regenerative medicine products in the UK, Regenerative Medicine, 4(4): 549–559.

    Article  Google Scholar 

  • Rajan, S. K. (2006) Biocapital: The Constitution of Postgenomic Life. Durham: Duke University Press.

    Book  Google Scholar 

  • Redhead, K. (2008) Personal Finance and Investments — A Behavioural Finance Perspective. Abingdon: Routledge.

    Book  Google Scholar 

  • Sheyn, D., O. Mizrahi, S. Benjamin, Z. Gazit, G. Pelled and D. Gazit (2010) Genetically modified cells in regenerative medicine and tissue engineering, Advanced Drug Delivery Reviews, 62(7–8): 683–698.

    Article  Google Scholar 

  • Suarez-Villa, L. (2009) Technocapitalism: A Critical Perspective on Technological Innovation and Corporatism. Philadelphia, PA: Temple University Press.

    Google Scholar 

  • Tait, J. (2007) System interactions in life science innovation, Technology Analysis and Strategic Management, 19(3): 257–277.

    Article  Google Scholar 

  • Takahashi, K., M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda and S. Yamanaka (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131: 861–872.

    Article  Google Scholar 

  • Talmor, E. and C. J. Cuny (April 2005) The staging of venture capital financing: Milestone vs. Rounds. EFA 2005 Moscow Meetings Paper. Available at SSRN http://ssrn.com/abstract=487414 or http://dx.doi.org/10.2139/ssrn.487414, accessed 3 June 2009.

    Google Scholar 

  • Taylor, B. (n.d.) Bull and Bear markets, past and present. Available at https://www.globalfinancialdata.com/articles/bull_and_bear_markets.doc, accessed 10 October 2009.

  • Tutton, R. (2011) Promising pessimism: reading the futures to be avoided in biotech, Social Studies of Science, 41(3): 411–429.

    Article  Google Scholar 

  • Van Lente, H. (1993) Promising Technology: The Dynamics of Expectations in Technological Developments. Enschede, Netherlands: Proefschrift Universiteit Twente.

    Google Scholar 

  • Van Merkerk, R. and D. Robinson (2006) Characterizing the emergence of a technological field: expectations, agendas and networks in lab-on-a-chip technologies, Technology Analysis and Strategic Management, 18(3–4): 411–428.

    Article  Google Scholar 

  • Waldby, C. and M. Robert (2006) Tissue Economies: Blood, Organs, and Cell Lines in Late Capitalism. Durham: Duke University Press.

    Book  Google Scholar 

  • Webster, A., C. Haddad and C. Waldby (2011) Experimental heterogeneity and standardisation: stem cell products and the clinical trial process, BioSocieties, 6(4): 401–419.

    Article  Google Scholar 

  • Whitaker, M. (2011) Stem cell therapies: to the clinic through the clinic. Keynote presentation at the REMEDiE International Conference Bringing Regenerative Medicine to the Clinic: Trials and Tribulations in Europe and Beyond; 18–19 April, Bilbao, Spain.

    Google Scholar 

  • Williams, D. J. and I. M. Sebastine (2005) Tissue engineering and regenerative medicine: manufacturing challenges, IEE Proceedings Nanobiotechnology, 152(6): 207–210.

    Article  Google Scholar 

  • Yu, J., M. A. Vodyani, K. Smuga-Otto, J. Antosiewicz-Bourget, J. L. Frane, S. Tian, J. Nie, G. A. Jonsdottir, V. Ruotti, R. Stewart, et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells, Science, 318: 1917–1920.

    Article  Google Scholar 

Download references

Authors
  1. Michael Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stuart Hogarth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beth Kewell
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of York, UK

    Andrew Webster

Copyright information

© 2013 Michael Morrison, Stuart Hogarth, and Beth Kewell

About this chapter

Cite this chapter

Morrison, M., Hogarth, S., Kewell, B. (2013). Biocapital and Innovation Paths: The Exploitation of Regenerative Medicine. In: Webster, A. (eds) The Global Dynamics of Regenerative Medicine. Health, Technology and Society. Palgrave Macmillan, London. https://doi.org/10.1057/9781137026552_3

Download citation

Publish with us

Policies and ethics

Search

Navigation